158 related articles for article (PubMed ID: 19099202)
21. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group.
Pawinski A; Tumolo S; Hoesel G; Cervantes A; van Oosterom AT; Boes GH; Pecorelli S
Eur J Obstet Gynecol Reprod Biol; 1999 Oct; 86(2):179-83. PubMed ID: 10509788
[TBL] [Abstract][Full Text] [Related]
22. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil.
Strumberg D; Harstrick A; Klaassen U; Müller C; Eberhardt W; Korn MW; Wilke H; Seeber S
Anticancer Drugs; 1997 Mar; 8(3):293-5. PubMed ID: 9095336
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas.
Hartmann JT; Oechsle K; Mayer F; Kanz L; Bokemeyer C
Anticancer Res; 2003; 23(2C):1899-901. PubMed ID: 12820475
[TBL] [Abstract][Full Text] [Related]
25. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
[TBL] [Abstract][Full Text] [Related]
26. Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
Ridola V; Fawaz O; Aubier F; Bergeron C; de Vathaire F; Pichon F; Orbach D; Gentet JC; Schmitt C; Dufour C; Oberlin O
Eur J Cancer; 2009 Mar; 45(5):814-8. PubMed ID: 19216070
[TBL] [Abstract][Full Text] [Related]
27. Oral cyclophosphamide therapy for patients with residual or relapsed indolent-type lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients with apparent transformed indolent lymphoma.
Riccioni R; Galimberti S; Cervetti G; Fazzi R; Caracciolo F; Petrini M
Leuk Lymphoma; 2002 Sep; 43(9):1803-6. PubMed ID: 12685835
[TBL] [Abstract][Full Text] [Related]
28. Ifosfamide in the treatment of head and neck cancer.
Airoldi M; Cortesina G; Giordano C; Pedani F; Bumma C
Oncology; 2003; 65 Suppl 2():37-43. PubMed ID: 14586145
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of ifosfamide for treatment of various canine neoplasms.
Rassnick KM; Frimberger AE; Wood CA; Williams LE; Cotter SM; Moore AS
J Vet Intern Med; 2000; 14(3):271-6. PubMed ID: 10830540
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
[TBL] [Abstract][Full Text] [Related]
31. Relevance of intraocular involvement in the management of primary central nervous system lymphomas.
Ferreri AJ; Blay JY; Reni M; Pasini F; Gubkin A; Tirelli U; Calderoni A; Zucca E; Cortelazzo S; Chassagne C; Tinguely M; Borisch B; Berger F; Ponzoni M; Cavalli F;
Ann Oncol; 2002 Apr; 13(4):531-8. PubMed ID: 12056702
[TBL] [Abstract][Full Text] [Related]
32. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
[TBL] [Abstract][Full Text] [Related]
33. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
[TBL] [Abstract][Full Text] [Related]
34. Ifosfamide in the treatment of lymphoma.
Coiffier B
Semin Oncol; 1996 Jun; 23(3 Suppl 7):2-7. PubMed ID: 8711498
[TBL] [Abstract][Full Text] [Related]
35. Treatment of invasive thymoma with single-agent ifosfamide.
Highley MS; Underhill CR; Parnis FX; Karapetis C; Rankin E; Dussek J; Bryant B; Rowland C; Hodson N; Hughes J; Harper PG
J Clin Oncol; 1999 Sep; 17(9):2737-44. PubMed ID: 10561348
[TBL] [Abstract][Full Text] [Related]
36. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
37. Ifosfamide in hematological malignancies of adults.
Rodeghiero F; Elice F
Oncology; 2003; 65 Suppl 2():85-93. PubMed ID: 14586156
[TBL] [Abstract][Full Text] [Related]
38. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
Vose JM
Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446
[TBL] [Abstract][Full Text] [Related]
39. Single-agent ifosfamide in the treatment of anthracycline-refractory adult sarcomas.
Lopez M; Carpano S; Amodio A; Gionfra T; Della Giulia M; Foggi P; Manfredi C; Del Monte G
Clin Ter; 1998; 149(5):331-3. PubMed ID: 10052244
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.
Biagi JJ; Herbert KE; Smith C; Abdi E; Leahy M; Falkson C; Wolf M; Januszewicz H; Seymour JF; Richards K; Matthews JP; Dale B; Prince HM
Leuk Lymphoma; 2005 Feb; 46(2):197-206. PubMed ID: 15621802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
